(ASTC) Announces OEM Agreement

AUSTIN, Texas, Jan. 29, 2014  — 1^st Detect Corporation, a subsidiary of Astrotech Corporation (Nasdaq:ASTC) announced today that the company has entered into a strategic OEM agreement with RIGAKU Corporation of Tokyo, Japan. The 1^st Detect OEM-1000PI mass spectrometer has been integrated with RIGAKU’s Thermogravimetric Analyzer (TGA) to offer a higher performance, smaller and more cost effective solution than what is currently available in today’s world market.

1^st Detect and RIGAKU have co-developed the successful integration of our respective technologies and have now completed the development of a highly capable and very competitively Thermogravimetric Analyzer. The integrated instrument named Thermo iMS² is the world’s first integrated TGA with MS/MS capabilities and is expected to be well received by the international research and development markets.

“We are extremely pleased to be working with RIGAKU, a world recognized leader in chemical analysis instrumentation. This agreement marks a significant milestone in both our corporate progress and is a major endorsement of 1^st Detect’s miniature mass spectrometer technology,” said Thomas B. Pickens III, Chairman and CEO of 1^st Detect.

The OEM-1000PI, is a mass spectrometer component that is based on 1^st Detect’s revolutionary MMS-1000™ instrument, and was customized to integrate RIGAKU’s stringent specifications including photo-ionization, atmospheric pressure sample introduction and a wider mass range than today’s state of the art cylindrical ion trap mass spectrometry.

“We are proud to have had the opportunity to leverage our expertise in miniature mass spectrometry to provide a world-class chemical analyzer to RIGAKU,” added David Rafferty, President & CTO of 1^st Detect, “by integrating our breakthrough technologies, RIGAKU is able to offer a TGA system that provides more performance, in a smaller instrument, than the competition.”

1^st Detect Corporation has developed an instrument that revolutionizes the chemical detection and analysis market by delivering lab performance mass spectrometry in a small, fast and affordable instrument. The 1^st Detect mass spectrometer’s broad capabilities make it an ideal tool for a variety of applications in the research, security, industrial, process flow and healthcare markets; and is capable of detecting a wide variety of chemicals including residues and vapors from plastics and polymers.

About 1^st Detect Corporation

1^st Detect Corporation was formed by Astrotech Corporation (Nasdaq:ASTC) to develop and commercialize miniature mass spectrometer technology first developed under an agreement with NASA for use on the International Space Station. 1^st Detect offers a breakthrough miniature mass spectrometer that fills an unmet need by being highly accurate, rapid, lightweight, and affordable.  For more information on 1^st Detect Corporation, please visit www.1stDetect.com.

About Astrotech Corporation

Astrotech is one of the first space commerce companies and remains a strong entrepreneurial force in the aerospace industry. We are leaders in identifying, developing and marketing space technology for commercial use. Our Astrotech Space Operations business unit serves our government and commercial satellite and spacecraft customers with pre-launch services on the eastern and western range. 1^st Detect Corporation has developed a breakthrough miniature mass spectrometer, while Astrogenetix, Inc. is a biotechnology company utilizing microgravity as a research platform for drug discovery and development.

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and funding for key space programs, product performance and market acceptance of products and services, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.

CONTACT: FOR MORE INFORMATION:
         Joshua Elbaum
         VP, Marketing
         +1 (512) 485-9530
         jelbaum@1stdetect.com

(ATNM) Engages Goodwin Biotechnology to Supply Iomab™-B for Its Phase 3 Clinical Study

Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company entered into a manufacturing supply agreement with Goodwin Biotechnology, Inc. (“Goodwin”). According to the agreement, Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab™-B. Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant (HSCT), commonly referred to as bone marrow transplant (BMT).

“This agreement with Goodwin represents a major risk mitigation step in conducting our phase 3 trial of Iomab™-B,” said Kaushik J. Dave, President and CEO of Actinium. “Goodwin has significant experience in working with companies like ours and the capabilities to provide the scale-up needed for a late-stage clinical trial. Goodwin’s competencies in process and product implementation, quality assurance, and GMP manufacturing make it ideally suited as a manufacturing partner for Actinium as we look forward to launching this pivotal phase 3 trial later this year.”

“We are very excited to be working with Actinium on Iomab™-B, their lead product candidate,” said Karl Pinto, CEO of Goodwin. “Actinium’s cutting edge proprietary platform is able to target different types of cancers that are without any approved treatment options. We look forward to a long-term partnership with Actinium, not only on Iomab™-B, but hopefully also on other products in their pipeline such as Actimab-A.”

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution™ through partnerships with clients for cell line development or exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines and Antibody Drug Conjugates (ADCs) for early and late stage clinical trials. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies as well as a roadmap to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients’ lives. With over 20 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Additional information may be found at www.GoodwinBio.com.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial. For more information, please visit www.actiniumpharmaceuticals.com.

About Iomab™-B

Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant which is the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission will include a single, pivotal Phase 3 clinical study if it is successful. The trial population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The study design of the pivotal trial is based on results of an earlier Phase 1/2 trial in which sixty percent of the older patients with refractory and relapsed AML exhibited disease free survival estimated at six months. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months. There are currently no treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab™-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to a bone marrow transplant in various blood cancers including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab™-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Iomab™-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine 131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

(IMMY) to Exhibit Pre-Commercial Ophthalmic Formulations

-Company Continues Go Dropless™ Information Campaign Targeted at Ophthalmologists-

SAN DIEGO, Jan. 28, 2014  — Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the ACES/SEE Caribbean Eye Meeting (http://caribbeaneyemeeting.com/) in Cancun, Mexico, January 31 to February 4, 2014. Imprimis will continue its Go Dropless™ campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.

Imprimis previously announced its plans to launch its proprietary ophthalmic sterile injectable compounded formulations during the first half of 2014. These therapies, designed for ophthalmic surgery patients, include a formulation combining triamcinolone acetonide and moxifloxacin hydrochloride. A similar combination adds the antibiotic vancomycin. Both of these drug formulations have been used by physicians during cataract surgeries and many other eye surgeries where there is inflammation and a chance for post-operative infection.  Imprimis anticipates also offering a suite of lyophilized mydriatic drug formulations using either epinephrine or phenyepherine, both of which may be combined with lidocaine.

The Caribbean Eye Meeting attendance continues the strong momentum Imprimis has been building from previous meetings, including the American Academy of Ophthalmology in New Orleans, Louisiana and “Cataract Surgery: Telling It Like It Is” in Sarasota, Florida. The company has also held several Ophthalmic Advisory Board meetings with national thought leaders. Each of these events provides the opportunity to build relationships and gain valuable insight on the company’s innovations and business model from the perspective of the cataract surgeons who participate.

For those interested in scheduling meetings with Imprimis at the ACES/SEE Caribbean Eye Meeting, please register at http://dropless.com/go-dropless/.

As the company previously stated when it acquired the intellectual property for these formulations in August 2013, the current treatment regimen for the prevention of post-cataract surgery complication is primarily a costly pre-operative and post-operative self-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack a supportive care giver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues.  Imprimis’ uniquely designed drug formulations utilize a fourth generation quinolone therapy combined with inflammatory suppression which provide new choices for physicians to address and resolve the primary ocular complications of ophthalmic surgery: infection risk and post-operative inflammation.

Imprimis believes that its formulations may have broad application in ophthalmic surgery, including the multi-billion global cataract surgery drug market.  The cataract surgery market continues to grow tremendously. According to Market Scope, nearly 22 million cataract surgeries were performed globally in 2013[1]. This growth is not only because of the expanding aging population, but because the age at which patients demand cataract surgery has lowered, shown in a study by Mayo Clinic[2], portending the ophthalmology drug market to reach $19.8 billion in 2014.[3]

ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations. Imprimis’ patent-pending drug formulations are available today and are being prescribed by physicians. For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Imprimis’ ability to acquire, develop, commercialize and market new formulations and technologies, enter into strategic alliances and transactions, including arrangements with pharmacies, physicians and healthcare organizations, commercialize its formulations and technologies, obtain intellectual property protection for its assets, accurately estimate its expenses and cash burn and raise additional funds, as well as the success of additional research and development activities related to its formulations and technologies, the projected size of the potential market for its technologies and formulations, unexpected new data, safety and technical issues, regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

1. Market Scope 2013 Comprehensive Report on the Global Cataract Surgical Equipment Market

2. Increasing incidence of cataract surgery: Population-based study. Journal of Cataract & Refractive Surgery, 2013; 39 (9)

3. MarketsandMarkets, May 2010, Report Code PH1300

MEDIA CONTACT:  Jen Carroll
jcarroll@imprimispharma.com
858.704.4587

(SANM) Announces Appointment of New Chief Operating Officer

Contec Holdings, LTD, (“Contec” or the “Company”) the market leader in repair and refurbishment services business, today announced the appointment of Jyoti (JK) Kapoor as its Chief Operating Officer. Mr. Kapoor will assume this role effective immediately.

“We are delighted to have Mr. Kapoor join the Contec team” said Hari Pillai, President and Chief Executive Officer of Contec. “Mr. Kapoor’s outstanding operations experience gained over multiple international and U.S. assignments with leading edge technology companies, combined with his proven track record of scaling organizations in growth environments is perfectly matched to Contec’s needs as we embark on a period of rapid expansion and growth.”

“I am very pleased to join the Contec team,” said Mr. Kapoor. “Contec’s strong positive reputation with its blue-chip customers is indicative of the quality, cohesion and performance of the organization. I particularly like the detailed roadmap for accelerated investment and growth that leverages the experience and strength of the management team. I’m really looking forward to contributing to the success of the organization and unlocking the company’s enormous potential” added Mr. Kapoor.

Prior to joining Contec, Mr. Kapoor served as Global Vice President of Operations at ABB (NYSE:ABB) where he led photovoltaic inverter manufacturing operations and spearheaded dramatic improvements in customer satisfaction, profitability, working capital and product quality. Prior to that, Mr. Kapoor served in a number of Operations Management roles at Sanmina-SCI (NASDAQ:SANM), the California-based design and manufacturing services company and Iomega (NYSE:IOM), a global leader in data storage products for consumers and business enterprises. Mr. Kapoor holds an MBA in Operations Management from Thunderbird School of Global Management, Arizona and Bachelors in Chemical Engineering from MIT, India.

About Contec

Leveraging 35 years of experience in the cable industry and its industry leading test solutions such as QuickTest®, Contec is the market leader in the test, repair and refurbishment of customer premise equipment for the world’s leading cable, satellite and IP-based Multiple-System Operators (MSO’s). More recently, the company has expanded its services to include repair and refurbishment of a wide array of electronics hardware products. With an expanding network of service centers around the world, Contec is headquartered in Schenectady, New York. Learn more at www.gocontec.com.

(YRCW) TNFINC Certifies Ratification of Worldwide Contract Terms

OVERLAND PARK, Kan., Jan. 28, 2014  — YRC Worldwide Inc. (Nasdaq:YRCW) announced today that the Teamsters National Freight Industry Negotiating Committee (TNFINC) certified the results of the Teamsters ratification vote and that, on a related note, the certified Amended Memorandum of Understanding (MOU) satisfied the relevant condition of the equity transaction announced on December 23^rd.

“The ratification of the revised MOU, our improved performance and the committed equity transaction clear the way for us to enter the senior debt markets to refinance our current term and asset-based loans,” said Jamie Pierson, chief financial officer of YRC Worldwide.

As previously announced on December 23, 2013, the company has entered into agreements whereby the company would issue $250 million of common stock and preferred stock and use the proceeds to pay off its existing 6% Convertible Notes due February 2014 and defease and/or pay off its existing Series A Convertible Notes due March 2015. In addition, holders of approximately $50 million in principal amount of the company’s existing Series B Convertible Notes due March 2015 have agreed to exchange or convert those notes to common stock, further reducing the company’s debt. The investors have confirmed that the revised MOU is satisfactory under the terms of these existing agreements.

The company plans to hold a bank meeting on Tuesday, January 28, 2014, at 2:00pm EST to launch the new senior credit facilities.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “will,” “would,” “anticipate,” “expect,” “believe,” “intend” and similar expressions are intended to identify forward-looking statements. It is important to note that actual efficiencies from the new agreement, results of the contingencies to obtaining the efficiencies, closing of the proposed equity transaction discussed in this news release, our ability to restructure our pension fund debt and refinance our senior debt, and the overall results of our refinancing strategy, including the amount our existing stockholders will be diluted, will be determined by a number of factors, including (among others) those risk factors that are from time to time included in the company’s reports filed with the SEC, including the company’s reports on Forms 10-K and 10-Q and the company’s Current Report on Form 8-K filed on December 9, 2013.  Further, the company cannot provide you with any assurances that the efficiencies will be achieved, that the conditions contained in the definitive agreements related to the proposed equity transaction will be satisfied or that the proposed equity transaction, the pension fund debt restructuring or the senior debt refinancing can be completed in the timeframes required under the company’s various agreements with its stakeholders, if at all.  In addition, even if all the contemplated transactions are completed, the company’s future results could differ materially from any results projected in such forward-looking statements because of a number of factors, including (among others) the risk factors that are from time to time included in the company’s aforementioned reports.

About YRC Worldwide

YRC Worldwide Inc., a Fortune 500 company headquartered in Overland Park, Kan., is the holding company for a portfolio of successful companies including YRC Freight, YRC Reimer, Holland, Reddaway, and New Penn. YRC Worldwide has one of the largest, most comprehensive less-than-truckload (LTL) networks in North America with local, regional, national and international capabilities. Through its team of experienced service professionals, YRC Worldwide offers industry-leading expertise in heavyweight shipments and flexible supply chain solutions, ensuring customers can ship industrial, commercial and retail goods with confidence. Please visit www.yrcw.com for more information.

Follow YRC Worldwide on Twitter: http://twitter.com/yrcworldwide

CONTACT: Investor Contact:
         Stephanie Fisher
         913-696-6108
         investor@yrcw.com

         Media Contact:
         Suzanne Dawson
         LAK Public Relations, Inc.
         212-329-1420
         sdawson@lakpr.com

(ALIM) Announces $37.5 Million Private Placement

ATLANTA, Jan. 28, 2014  — Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately $37.5 million of its common stock in a private placement. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.

“This financing will provide us with working capital to support our continued commercialization of ILUVIEN® in Europe and the ongoing pursuit of FDA approval in the United States,” said Dan Myers, president and chief executive officer of Alimera.

Alimera has entered into a securities purchase agreement with the investors pursuant to which Alimera will sell an aggregate of 6,250,000 shares of its common stock at a purchase price of $6.00 per share. The private placement is subject to customary closing conditions and is expected to close during the week of January 27, 2014.

Cowen and Company, LLC served as sole placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Alimera nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The common stock offered in the private placement has not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission (SEC) or through an applicable exemption from SEC registration requirements. The shares of common stock were offered only to accredited investors. Alimera has agreed to file a registration statement with the SEC covering the common stock purchased by the investors. Any offering of Alimera’s securities under the resale registration statement will be made only by means of a prospectus.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Forward Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the anticipated closing of, and proposed use of proceeds from, the private placement, Alimera’s commercial plans for ILUVIEN in Europe and the regulatory status of ILUVIEN in the United States. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include risks related to the satisfaction of the conditions to, and the timing of, the closing of the private placement, Alimera’s need for additional capital in the future, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Alimera’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

(IDIX) to Raise $106.7 Million Through Registered Direct Offering

CAMBRIDGE, Mass., Jan. 28, 2014  — Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has entered into a definitive agreement with certain entities managed by The Baupost Group, L.L.C. (Baupost) for the sale of 16,420,241 shares of its common stock. Baupost has agreed to purchase the shares of common stock at a price of $6.50 per share, resulting in net proceeds to Idenix, after deducting estimated offering expenses, of approximately $106.7 million.

Baupost, which currently owns approximately 27% of the Company’s outstanding common stock, will beneficially own approximately 35% of the Company’s outstanding common stock upon completion of the offering. The sale and issuance of the shares is expected to close on or about January 31, 2014, subject to customary closing conditions. The proceeds of this offering will be used for general corporate purposes, including clinical trial costs and ongoing and future patent litigation expenses. The Company believes that its current cash and cash equivalents balance and the net proceeds from this offering will be sufficient to satisfy cash needs into at least the second half of 2015.

Pursuant to a letter of agreement between the parties, the Company has agreed that Baupost, for so as long as it holds at least 25% of the Company’s outstanding common stock, is entitled to observer rights with respect to meetings of the board of directors of the Company.

The securities described above are being offered directly to the purchasers by Idenix pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). This press release is not an offer to sell any of the securities described herein, and this press release is not an offer to buy these securities in any state where the offer or sale is not permitted. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained by visiting EDGAR on the SEC’s website at www.sec.gov.

ABOUT IDENIX

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix’s current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, without limitation, the completion, timing and size of the Company’s proposed offering and the use of proceeds therefrom. In some cases, words such as “will,” “expect” or other comparable words identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various important factors, including without limitation risks and uncertainties relating to the Company’s business and financial condition, general market conditions and the satisfaction of customary closing conditions associated with the proposed offering. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not the Company will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed offering and the impact of general economic, industry or political conditions in the United States or internationally. Risks and uncertainties that the Company faces are described in greater detail under the heading ” Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2012 and the quarterly report on Form 10-Q for the quarter ended September 30, 2013, each as filed with the SEC and in any subsequent periodic or current report that the Company files with the SEC. As a result of the risks and uncertainties, the results or events indicated by any forward-looking statement may not occur. The Company cautions you not to place undue reliance on any forward-looking statement.

All forward-looking statements reflect the Company’s views only as of the date of this release and should not be relied upon as reflecting the Company’s views, expectations or beliefs at any date subsequent to the date of this release. While the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the Company’s views, expectations or beliefs change.

CONTACT: Idenix Pharmaceuticals Contact:
         Teri Dahlman (617) 995-9807

(BGMD) Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study

WALTHAM, Mass., Jan. 28, 2014 — BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3^® Test, welcomed today the publication of results of a clinical research study that demonstrate and validate the analytical and clinical performance of the automated VIDAS^® Galectin-3 assay that was developed by bioMérieux SA, a world leader in the field of in vitro diagnostics and one of BG Medicine’s automation partners.

In this clinical research study, published online ahead of print in the journal Clinica Chimica Acta, elevated galectin-3 levels in previously collected blood samples, measured using the VIDAS^® Galectin-3 assay, were reported to be significantly predictive of fatal cardiovascular events and severity of heart failure among the 137 patients diagnosed with chronic heart failure who were tested.[1] The prognostic information provided by the VIDAS^® Galectin-3 assay in this published clinical research study was found to be complementary and additive to that obtained by measurement of three different types of natriuretic peptides, including BNP, NT-proBNP and proBNP. The significant predictive value of galectin-3 levels was further demonstrated to be independent of other key clinical parameters, such as impaired kidney function, reduced cardiac left ventricular pumping capacity, and age. When evaluated for analytical performance, measurement values obtained with the VIDAS^® Galectin-3 assay were found to be in excellent agreement with those obtained with the BGM Galectin-3^® Test.

“We are very pleased with the results obtained with the automated VIDAS^® Galectin-3 assay in this clinical research study,” said Dr. Paul R. Sohmer, President and CEO of BG Medicine, Inc. “These results support commercialization of the VIDAS^® Galectin-3 assay in Europe and substantiate our efforts to assist bioMérieux with its pursuit of 510(k) clearance of the assay in the U.S.”

The VIDAS^® Galectin-3 assay was developed by bioMérieux for the quantitative measurement of galectin-3 levels in blood using the bioMérieux VIDAS automated and multiparametric immunoassay testing system. The VIDAS^® Galectin-3 assay requires 200 microliters of blood plasma or serum and is designed to return test results within 20 minutes. [2] This automated and quantitative assay for galectin-3 in blood is CE Marked and currently available in Europe as an aid in assessing the prognosis of patients diagnosed with chronic heart failure when used in conjunction with clinical evaluation.

[1] Gruson D, Mancini M, Ahn SA, Rousseau MF. Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction, Clin Chim Acta (2013), http://dx.doi.org/10.1016/j.cca.2013.12.017.

[2] bioMérieux SA. (2014). VIDAS® Galectin-3. Retrieved from http://www.biomerieux-diagnostics.com/servlet/srt/bio/clinical-diagnostics/dynPage?open=CNL_CLN_PRD&doc=CNL_CLN_PRD_G_PRD_CLN_99&pubparams.sform=0&lang=en.

About Galectin-3 and Heart Failure

Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure. Higher levels of galectin-3 are associated with a more aggressive form of heart failure, which may make identification of high-risk patients using galectin-3 testing an important part of patient care. Galectin-3 testing may be useful in helping physicians determine which patients are at higher risk of death or hospitalization, including 30-day hospital readmission.

The BGM Galectin-3^® Test quantitatively measures galectin-3 protein concentrations in blood serum and plasma. It is cleared by the U.S. FDA as an aid in assessing the prognosis of patients diagnosed with chronic heart failure when used in conjunction with clinical evaluation. The BGM Galectin-3 Test is also CE Marked and available in Europe as an aid in assessing the prognosis of patients diagnosed with acute and chronic heart failure when used in conjunction with clinical evaluation, and as an aid in assessing the risk of new onset heart failure in adults.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3^® Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.BG-Medicine.com. The BG Medicine Inc. logo is available for download here.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: our belief that the results of the published clinical research study discussed herein support the commercialization of the bioMérieux VIDAS^® Galectin-3 assay. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include, among other things, the factors discussed under the heading “Risk Factors” contained in BG Medicine’s annual report and quarterly reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and BG Medicine disclaims any obligation to update the information contained in this press release as new information becomes available.

CONTACT: Corporate Communications
         +1 (781) 890-1199
         BG Medicine, Inc.

(MLNX) World’s First 40 Gigabit Ethernet NIC Based on Open Compute Project

Mellanox® Technologies, Ltd. (NASDAQ: MLNX), a leading supplier of high-performance, end-to-end interconnect solutions for data center servers and storage systems, today announced it is offering its 40GbE NIC as a proposed contribution to the Open Compute Project. The new 40GbE NIC is based on Mellanox’s energy-efficient, high-performance ConnectX®-3 Pro ICs, and is designed to meet OCP specifications. Available now, the ConnectX®-3 Pro OCP-based 40GbE NICs with RDMA over Converged Ethernet (RoCE) and overlay network offloads offer optimized latency and performance for converged I/O infrastructures while maintaining extremely low system power consumption.

“Mellanox has been active in the OCP Network Project and has contributed to the open hardware and software model to help achieve OCP’s vision for true open standards and faster pace in network technology innovation,” said Kevin Deierling, vice president of marketing at Mellanox Technologies. “We’re pleased to continue our collaborations with Facebook in delivering 40GbE NIC technology to OCP to deliver unmatched performance and rich feature-sets that enable superior data center productivity and efficiency.”

“Mellanox has played an important role in a number of OCP projects, including our new networking project,” said Frank Frankovsky, president and chairman of the Open Compute Project Foundation. “We’re pleased to see them propose the 40GbE OCP-based NIC as a contribution to OCP and look forward to collaborating with them further as we work to make open hardware a reality.”

Visit Mellanox Technologies at the OCP Summit (January 28-29, 2014)

Visit Mellanox during the OCP Summit (booth #C21) from January 28-29 at the San Jose Convention Center to learn more about its OCP-compliant 10 and 40GbE NICs. Mellanox will also exhibit its SX1024-OCP, SwitchX®-2-based Top-of-Rack switch, which supports 48 10GbE SFP+ ports and up to 12 40GbE QSFP ports, enabling non-blocking connectivity within the OCP’s Open Rack, or alternatively, enabling 60 10GbE server ports when using QSFP+ to SFP+ breakout cables to increase rack efficiency for less bandwidth demanding applications. Mellanox will also exhibit its SX1036-OCP, SwitchX®-2-based spine switch, which supports 36 40GbE QSFP ports, enabling non-blocking connectivity between the racks. The new switches are also the first that support Open Network Install Environment (ONIE) over x86 processors, which will enable new levels of scalability and performance.

Supporting Resources:

• Learn more about Mellanox’s OCP 40GbE NIC
• Follow Mellanox on Twitter, Facebook, Google+, Linked-In, and YouTube
• Join the Mellanox Community

About Mellanox

Mellanox Technologies is a leading supplier of end-to-end InfiniBand and Ethernet interconnect solutions and services for servers and storage. Mellanox interconnect solutions increase data center efficiency by providing the highest throughput and lowest latency, delivering data faster to applications and unlocking system performance capability. Mellanox offers a choice of fast interconnect products: adapters, switches, software, cables and silicon that accelerate application runtime and maximize business results for a wide range of markets including high performance computing, enterprise data centers, Web 2.0, cloud, storage and financial services. More information is available at www.mellanox.com.

Mellanox, ConnectX and SwitchX are registered trademarks of Mellanox Technologies, Ltd. All other trademarks are property of their respective owners.

(GALT) and SBH Sciences Announce the Formation of Galectin Sciences, LLC

NORCROSS, Ga. and NATICK, Mass., Jan. 27, 2014 — Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, and SBH Sciences, Inc., a world leader in cell-based assays to measure biological activity and developer of cytokines, growth factors, biologics and monoclonal antibodies, jointly announce the establishment and formation of Galectin Sciences, LLC, a collaborative venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration.

Using computer molecular modeling techniques coupled with in vitro screening of a variety of compound libraries, SBH Sciences recently identified several small organic molecules with promising galectin-3 inhibitory activity in vitro. Galectins, a class of proteins made by many cells in the body, are known to be markedly increased in a number of diseases including scaring of organs and cancers of many kinds. Galectin Sciences, a Georgia-based LLC jointly owned by Galectin Therapeutics and SBH Sciences, will allow the companies to collaborate in further development of these unique organic molecule inhibitors of galectin-3 as drug candidates as well as discovery of additional candidates.

Galectin Sciences will build on the scientific body of knowledge amassed by SBH Sciences, coupled with Galectin Therapeutics’ knowledge and expertise of galectins’ pathological role and mechanism of action in inflammation, fibrosis and many cancers. The long-term goal of this effort is to identify and develop drug candidates that are highly specific galectin inhibitors which may be formulated for oral administration. The intermediate term goal is the development of small molecule inhibitors of galectin-3 which exhibit activity in in vivo preclinical disease models of fibrosis and cancer in which galectins play a key role.

Dr. Raphael Nir, President and Chief Science Officer, SBH Sciences, said: “We are excited and honored to partner with Galectin Therapeutics, a company that we have provided services for more than 10 years. This unique moment is a transformational point for SBH Sciences and represents the shift in our business model from service provider to biotechnology company. Targeting of galectin-3 by small organic compounds is a unique opportunity to resolve significant unmet medical needs, and Galectin Therapeutics is the ideal partner. I am confident that the mutual trust and the dedication of the two teams, combined with the vast expertise that has been built by SBH Sciences over the past 16 years, will enable us to potentially bring new galectin inhibitors into clinical development and human clinical trials.”

Galectin Therapeutics has a long standing interest in compounds that bind galectins, particularly galectin-3, which has resulted in two clinical development programs involving intravenous administration of the company’s proprietary galectin inhibitor compounds GM-CT-01 and GR-MD-02. Galectin Therapeutics is pursuing synthetic routes to newer large molecular weight carbohydrate entities as well as smaller carbohydrates which might be administered by alternate routes. Longer term, the company is also interested in developing small molecule inhibitors of galectin which may be orally active.

“The formation of Galectin Sciences represents a significant step forward in the research of galectin proteins and demonstrates both companies’ confidence in galectin inhibitors as potential treatment options for diseases with large unmet medical need,” said Dr. Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics. “Increased levels of galectin proteins have been implicated in a very large number of inflammatory, fibrotic and neoplastic diseases; the discovery and development of orally active galectin inhibitors would be a major step towards expanded treatment approaches for these disorders. This work may lead to drugs that would expand our pipeline as follow on compounds to our first in class galectin inhibitors, GR-MD-02 and GM-CT-01, which are currently in clinical trials.”

About Galectin Sciences, LLC

Galectin Sciences, a Georgia-based LLC, is a collaborative venture to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The venture, jointly owned by Norcross, Ga.-based Galectin Therapeutics, and Natick, Mass.-based SBH Sciences, was formed based on the scientific understanding of the role that galectin proteins play in a number of diseases including scaring of organs and cancers of many kinds. Galectin Sciences seeks to identify and develop unique organic molecule inhibitors of galectin-3 as drug candidates which may be formulated for oral administration in the treatment of certain human diseases.

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

About SBH Sciences, Inc.

SBH Sciences, Inc., located in Natick, Mass., and founded in 1997, is a biotechnology company and a preclinical Contract Research Organization. SBH Sciences has provided research products and services to over 120 pharmaceutical, biotechnology, and diagnostic clients across the globe, mainly in the fields of oncology and inflammation. SBH Sciences specializes in lead drug optimization through innovative cell based cytokine bioassays, biomarker profiling, and customized analytical method development including multiplex analysis. SBH Sciences is the world leader in cell-based assays and currently offers over 280 validated assays and 300 cell lines to evaluate biological activity of lead drugs, cytokines, growth factors, and other biologics. SBH Sciences’ proprietary processes have been utilized in commercial production of 31 cytokines, 9 recombinant Glycosyltransferase enzymes, 31 monoclonal antibodies and over 30 ELISA kits. In the last 3 years, SBH Sciences has assisted three biotechnology companies in advancing their lead compounds into phase I clinical trials. For further information, please see www.sbhsciences.com

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. These statements include those regarding the potential benefits of Galectin Sciences, LLC, or any drugs or treatments developed by Galectin Sciences, LLC or its parent companies, the potential to bring new galectin inhibitors into clinical development and human clinical trials, the promising nature of any studies or research, current, intermediate-term and long-term goals related to the new collaborative venture and/or Galectin Therapeutics, potential treatment options, research and development plans and the possibility of an expanded pipeline with new drugs or treatments. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that plans, expectations and goals regarding any research and development activities, preclinical data and potential therapeutic uses and benefits of any drugs and any future pre-clinical or clinical studies are subject to factors beyond the companies’ control. Future research efforts including preclinical or clinical studies may not begin or produce positive results in a timely fashion, if at all, and could prove time consuming and costly. Plans regarding development, approval and marketing of any drugs are subject to change at any time based on changing needs as determined by management and regulatory agencies. There is no guarantee that this new collaborative venture will be successful or that it will ultimately lead to meaningful revenue or earnings. Regardless of the results of current or future studies, success may not be achieved in developing partnerships with other companies or obtaining capital that would allow further development and/or funding for any studies or trials. To date, Galectin Therapeutics has incurred operating losses since its inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance its continuing operations. For a discussion of additional factors impacting Galectin Therapeutics’ business, see its Annual Report on Form 10-K for the year ended December 31, 2012, and its subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause views to change, the companies disclaim any obligation to update forward-looking statements.

CONTACT: Galectin Therapeutics Inc.
         Peter G. Traber, MD, 678-620-3186
         President, CEO, & CMO
         ir@galectintherapeutics.com

(SLTC) Completes $8.7 Million Equity Financing

Capital to Fuel SaaS Customer Growth and Platform Investment

(CPAH) Recognized as Leading Softphone Client Product for Its BlackBerry and SaaS Offerings

TMC Awards CounterPath with Two Product of the Year Awards Further Validating CounterPath’s Strength in the Unified Client Market

CounterPath Corporation
Hill + Knowlton Strategies
Dana Sissons
(604) 692-4236
pr@counterpath.com

(GAME) Announces Receipt of Non-Binding Proposal to Acquire the Company

SHANGHAI, Jan. 27, 2014 /PRNewswire/ — Shanda Games Limited (NASDAQ: GAME, “Shanda Games” or the “Company”), a leading online game developer, operator and publisher in China, today announced that its Board of Directors (the “Board”) has received a preliminary non-binding proposal letter dated January 27^th, 2014 (the “Proposal”) from Shanda Interactive Entertainment Limited, the controlling shareholder of the Company, and an affiliate of Primavera Capital Limited (together, the “Consortium”). According to the Proposal, the Consortium proposed to acquire the Company in a “going private” transaction for US$3.45 per class A or class B ordinary share, or US$6.90 per American depositary shares (each representing two class A ordinary shares) (each an “ADS”). Based on the offer price, the Proposal values the Company at approximately US$1.9 billion in fully enlarged equity value. According to the Proposal, the offer price represents a premium of 21.3% to the Company’s volume-weighted average price of its ADSs on January 24, 2014 and a premium of 44.4% to the volume-weighted average price of its ADSs during the last 30 trading days.

As of January 27, 2014, the Consortium members beneficially owned, in the aggregate, approximately 76.2% of the Company’s outstanding shares.

According to the Proposal, the proposed transaction is intended to be financed with a combination of equity capital funded by the Consortium members and third-party debt. The Consortium’s proposal letter states that its proposal constitutes only a preliminary indication of its interest and is subject to negotiation and execution of definitive agreements relating to the proposed transaction. A copy of the proposal letter is attached hereto as Exhibit A.

The Board is reviewing and evaluating the Consortium’s Proposal, and the Company expects that the Board will form a special committee consisting of independent directors to evaluate and, if appropriate, negotiate the Proposal and to consider other strategic options available to the Company.

The Company cautions its shareholders and others considering trading its securities that the Board has just received the proposal letter and has not made any decision with respect to the Company’s response to the Proposal. There can be no assurance that any definitive offer will be made by the Consortium or any other person, that any definitive agreement will be executed relating to the proposed transaction, or that the proposed transaction or any other transaction will be approved or consummated.

According to the proposal letter, Wilson Sonsini Goodrich & Rosati, P.C. is acting as U.S. counsel to Shanda Interactive Entertainment Limited and the Consortium as a whole, and Latham & Watkins is serving as U.S. counsel to Primavera Capital Limited. Davis Polk & Wardwell LLP is the Company’s U.S. counsel.

Safe Harbor Statement

This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release that are not historical facts represent only the Company’s current expectations, assumptions, estimates and projections and are forward-looking statements. These forward-looking statements involve inherent risks and uncertainties. Important risks and uncertainties that could cause the Company’s actual results to be materially different from expectations include, but are not limited to, the risks set forth in the Company’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

This press release is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the issuer or selling security holder and that will contain detailed information about the company and management, as well as financial statements.

About Shanda Games

Shanda Games Limited (NASDAQ: GAME) is a leading online game developer, operator and publisher in China. Shanda Games offers a diversified game portfolio, which includes some of the most popular massively multiplayer online (MMO) games and mobile games in China and in overseas markets, targeting a large and diverse community of users. Shanda Games manages and operates online games that are developed in-house, co-developed with world-leading game developers, acquired through investments or licensed from third parties. For more information about Shanda Games, please visit http://www.ShandaGames.com.

Contact

Shanda Games Limited:
Ellen Chiu, Investor Relations Director
Maggie Zhou, Investor Relations Associate Director
Phone: +86-21-5050-4740 (Shanghai)
Email: IR@ShandaGames.com

Christensen:
Christian Arnell
Phone: +86-10-5900-1548 (China)
Email: carnell@ChristensenIR.com

Linda Bergkamp
Phone: +1-480-614-3004 (U.S.A.)
Email: lbergkamp@ChristensenIR.com

Exhibit A

Preliminary Proposal

January 27, 2014

The Board of Directors
Shanda Games Limited
No. 1 Office Building, No. 690 Bibo Road
Pudong New Area, Shanghai 201203
People’s Republic of China

Dear Sirs:

Shanda Interactive Entertainment Limited (“Shanda Interactive“) and Primavera Capital (Cayman) Fund I L.P.  (the “Sponsor“) are pleased to submit this preliminary non-binding proposal to acquire Shanda Games Limited (the “Company“) in a going private transaction (the “Acquisition“).

We believe that our proposal provides a very attractive opportunity to the Company’s shareholders. Our proposal represents a premium of 21.3% to the Company’s volume-weighted average price on January 24, 2014 and a premium of 44.4% to the volume-weighted average price during the last 30 trading days.

1. Consortium.  Shanda Interactive and the Sponsor (collectively, the “Consortium Members“, and the consortium so formed, the “Consortium“) have entered into a consortium agreement (the “Consortium Agreement“) dated as of the date hereof, pursuant to which we will form an acquisition company for the purpose of implementing the Acquisition, and have agreed to work with each other exclusively in pursuing the Acquisition.  The Consortium Agreement also obligates the Consortium Members to (i) vote for the proposed Acquisition and not take any action inconsistent with it, (ii) not transfer any of their respective shares in the Company unless as otherwise permitted under the Consortium Agreement, and (iii) vote against any competing proposal or matter that would facilitate a competing proposal.
2. Purchase Price.  The consideration payable for each American Depositary Share of the Company (“ADS“, each representing two Class A ordinary shares of the Company) will be $6.90 in cash, or $3.45 in cash per Class A or Class B ordinary share (in each case other than those ADSs or shares held by the Consortium Members that may be rolled over in connection with the Acquisition pursuant to the Consortium Agreement).
3. Funding.  We intend to finance the Acquisition with a combination of debt and equity capital.  Equity financing would be provided from the Consortium Members and any additional members we accept into the Consortium.
4. Due Diligence.  We believe that we will be in a position to complete customary legal, financial and accounting due diligence for the Acquisition in a timely manner and in parallel with discussions on the definitive agreements.  Wilson Sonsini Goodrich & Rosati P.C. has been retained as international legal counsel to Shanda Interactive and the Consortium and Latham & Watkins as international legal counsel to the Sponsor.
5. Definitive Agreements.  We are prepared to promptly negotiate and finalize definitive agreements (the “Definitive Agreements“) providing for the Acquisition and related transactions. These documents will provide for representations, warranties, covenants and conditions which are typical, customary and appropriate for transactions of this type.
6. Process.  We believe that the Acquisition will provide superior value to the Company’s shareholders.  We recognize that the Company’s Board of Directors (the “Board“) will evaluate the Acquisition independently before it can make its determination to endorse it.  Given the involvement of Shanda Interactive in the Acquisition, we appreciate that the independent members of the Board will proceed to consider the proposed Acquisition.
   In considering our offer, you should be aware that the Consortium Members are interested only in acquiring the outstanding shares of the Company that the Consortium Members do not already own, and that the Consortium Members do not intend to sell their stake in the Company to any third party.
7. Confidentiality.  Shanda Interactive will, as required by law, promptly make a Schedule 13D filing to disclose this letter and its agreement with the Sponsor.  However, we are sure you will agree with us that it is in all of our interests to ensure that we proceed in a strictly confidential manner, unless otherwise required by law, until we have executed Definitive Agreements or terminated our discussions.
8. About Primavera.  Primavera Capital, established in 2010, is a China-based private investment firm focusing on investments in buy-out, control-oriented, and growth capital investments.
9. No Binding Commitment.  This letter constitutes only a preliminary indication of our interest, and does not constitute any binding commitment with respect to the Acquisition.  A binding commitment will result only from the execution of Definitive Agreements, and then will be on terms and conditions provided in such documentation.

In closing, we would like to express our commitment to working together to bring this Acquisition to a successful and timely conclusion.  Should you have any questions regarding this proposal, please do not hesitate to contact us.  We look forward to hearing from you.

Sincerely,

SHANDA INTERACTIVE ENTERTAINMENT LIMITED

(ORMP) Oral Insulin Phase 2a Clinical Trial Results Slated For Jan 30

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it will announce the results of its Phase 2a clinical trial for the company’s ORMD-0801 oral insulin capsule for the treatment of type 2 diabetes on January 30, 2014. Oramed CEO Nadav Kidron will present the findings at an investor conference taking place at the Tel Aviv Stock Exchange in Tel Aviv, Israel.

The Phase 2a trial was conducted in the U.S. under the auspices of the FDA and was designed to show the drug’s overall safety profile. Thirty patients with type 2 diabetes took part in the double-blind, randomized trial in an in-patient setting for one week of treatment.

About ORMD-0801 Oral Insulin

Oramed’s ORMD-0801 is an orally ingestible insulin capsule for the early stages of type 2 diabetes, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite. Moreover, orally administered insulin has the potential benefit of enhanced patient compliance at this crucial stage as well as the advantage of mimicking insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream. For more information on ORMD-0801, the content of which is not part of this press release, please visit:  http://oramed.com/index.php?page=14

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD^TM) technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog) currently scheduled to start IND-enabling trials. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes (T1DM). The company’s corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the expected timing for announcement of our Phase2a clinical trial, when we discuss the potential benefits of orally administered insulin, when we discuss our clinical trials or revolutionizing the treatment of diabetes with our products. These forward-looking statements and their implications are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office: +972-2-566-0001
US: +1-718-831-2512
Email: aviva@oramed.com

(NRK) Board Approves Leverage Refinancing Plan for Four CEFs

Nuveen Investments, a leading global provider of investment services to institutions as well as individual investors, today announced that the Board of Trustees of four Nuveen municipal bond closed-end funds has approved a refinancing plan to redeem all of their respective MuniFund Term Preferred (MTP) shares and Variable Rate MuniFund Term Preferred (VMTP) shares. MTP shares will be redeemed at their $10.00 liquidation value per share plus an additional amount representing any dividend amounts owed. VMTP shares will be redeemed at their $100,000 liquidation value per share plus an additional amount representing any dividend amounts owed. The redemption of both MTP shares and VMTP shares will be made with the proceeds of newly issued preferred shares, subject to completion of all aspects of their placement, which may not occur as planned.

The funds intending to redeem MTP and VMTP shares and a description of their outstanding preferred shares are as follows:

The funds intend to offer newly issued preferred shares to qualified institutional buyers in private offerings pursuant to Rule 144A of the Securities Act of 1933. Details regarding specific terms and timing of the redemptions will be communicated at a later date through filings with the Securities and Exchange Commission, and accompanied by a public press release at that time.

No preferred shares to be offered have been registered under the Securities Act of 1933 (the Securities Act) or any state securities laws. Unless so registered, no preferred shares may be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. This press release is neither an offer to sell nor a solicitation of an offer to buy any of these securities.

Nuveen Investments provides high-quality investment services designed to help secure the long-term goals of institutional and individual investors as well as the consultants and financial advisors who serve them. Nuveen Investments markets a wide range of specialized investment solutions which provide investors access to capabilities of its high-quality boutique investment affiliates—Nuveen Asset Management, LLC, Symphony Asset Management LLC, NWQ Investment Management Company, LLC, Santa Barbara Asset Management, LLC, Tradewinds Global Investors, LLC, Winslow Capital Management, LLC and Gresham Investment Management LLC, all of which are registered investment advisers and subsidiaries of Nuveen Investments, Inc. Funds distributed by Nuveen Securities, LLC, a subsidiary of Nuveen Investments, Inc. In total, Nuveen Investments managed nearly $215 billion as of September 30, 2013. For more information, please visit the Nuveen Investments website at www.nuveen.com.

FORWARD LOOKING STATEMENTS

Certain statements made in this release are forward-looking statements. Actual future results or occurrences may differ significantly from those anticipated in any forward-looking statements due to numerous factors. These include, but are not limited to:

• the acceptance by qualified institutional buyers of, and demand for, preferred shares in amounts sufficient for each fund to refinance its MTP and VMTP shares;
• the need to obtain the agreement of all parties to the final terms of the offerings of preferred shares
• other legal and regulatory developments; and
• other additional risks and uncertainties.

Nuveen and the closed-end funds managed by Nuveen and its affiliates undertake no responsibility to update publicly or revise any forward-looking statement.

(PBCP) Announces Share Repurchase Plan

Polonia Bancorp, Inc. (NasdaqCM:PBCP) announced today that its board of directors approved the repurchase of up to 175,563 shares of the Company’s outstanding common stock, which is approximately 5% of outstanding shares. Purchases will be conducted through a Rule 10b5-1 repurchase plan with Sandler O’Neill & Partners, L.P., which will become effective following release of the Company’s report on earnings for the quarter and year ended December 31, 2013.

The Rule 10b5-1 repurchase plan allows the Company to repurchase its shares during periods when it would normally not be active in the market due to its internal trading blackout period. There is no guarantee as to the exact number of shares to be repurchased by the Company. Repurchased shares will be held in treasury.

(CXDC) Favor Sea Limited Announces Pricing of Guaranteed Senior Notes

HARBIN, China, Jan. 24, 2014  — China XD Plastics Company Limited (NASDAQ: CXDC or the “Company”), one of China’s specialty chemical players engaged in the development, manufacture and sale of modified plastics primarily for automotive applications, today announced that its wholly owned subsidiary, Favor Sea Limited (the “Issuer”), priced its international offering of guaranteed senior notes.

The offering consists of US$150 million aggregate principal amount of 11.75% guaranteed senior notes due 2019 (the “Notes”). The Issuer intends to use the net proceeds from the offering for repayment of indebtedness incurred by its PRC subsidiaries, for capital expenditure on a production base in Sichuan and for general corporate purposes.

The Notes will be guaranteed on a senior basis by the Company and Xinda Holding (HK) Company Limited, a subsidiary wholly owned by the Issuer (the “Subsidiary Guarantor”). The Notes will be secured by a pledge of the shares of the Issuer held by the Company and a pledge of the shares of the Subsidiary Guarantor held by the Issuer.

Approval-in-principle has been received for the listing of the Notes on the Singapore Exchange Securities Trading Limited (the “SGX-ST”). Admission of the Notes to the SGX-ST is not to be taken as an indication of the merits of the Issuer or the Notes.

The Notes are being offered in the United States to qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and outside of the United States pursuant to Regulation S under the Securities Act. The Notes have not been registered under the Securities Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state law. The Issuer does not intend to register any portion of the offering of the Notes in the United States.

Nothing in this announcement constitutes an offer to buy, or a solicitation of an offer to sell, securities in the United States or any other jurisdiction in which such offer or solicitation would be unlawful.

Kenan Gong
(86) 15004502872
ir@chinaxd.net

(LIVE) Forward Stock Split

(UQM) to Hold Conference Call Thursday, January 30, 2014 at 4:30 P.M. Eastern Time

UQM Technologies, Inc. (NYSE MKT:UQM), a developer of alternative energy technologies, will hold a conference call with members of the investment community on Thursday, January 30, 2014, at 4:30 p.m. Eastern Time. To participate in the call dial 1-877-941-6009 approximately 10 minutes before the conference is scheduled to begin and provide conference ID code “4664380” to access the call. International callers should dial 1-480-629-9819.

Eric R. Ridenour, UQM Technologies’ President and Chief Executive Officer, and David I. Rosenthal, Treasurer and Chief Financial Officer, will be reviewing the Company’s operating results for the quarter and nine months ended December 31, 2013.

For anyone who is unable to participate in the conference, access to a recording will be available for 7 days following the call. Dial 1-800-406-7325 and enter replay access code 4664380# to access the playback. International callers should dial +1-303-590-3030. Please allow one hour from the time of the conference call for initial setup before access.

About UQM

UQM Technologies is a developer and manufacturer of power-dense, high-efficiency electric motors, generators and power electronic controllers for the automotive, commercial truck, bus and military markets. A major emphasis for UQM is developing propulsion systems for electric, hybrid electric, plug-in hybrid electric and fuel cell electric vehicles. UQM is located in Longmont, Colorado.

Please visit www.uqm.com for more information.

(WAVX) Bill Solms, CEO Interview on Clear Channel Business Talk Radio

Interview at 2:15 pm CST / 3:15 pm EST on The Traders Network Radio Show, Hosted by Michael Yorba

(LIVE) Announces Three for One Forward Stock Split

(HOTR) Appalachian Mountain Brewery Purchases Cask Semi-Automated Canning System

BOONE, N.C., Jan. 23, 2014 — Appalachian Mountain Brewery, Inc. (OTC:HOPS), is pleased to announce it filed its Form-D with the U.S. Securities and Exchange Commission and North Carolina Securities Division. AMB officially began its Preferred B Stock-based offering and already secured significant initial expansion capital as part of an overall funding program. For additional information about the Preferred B Stock-based offering, accredited investors can contact AMB directly. The initial capitalization has allowed the company to make the purchase of additional brewing equipment and a Cask Semi-Automated Canning System (“SAMS”, www.cask.com) , which will significantly expand its capacity and allow AMB to offer distribution of four beer styles in cans throughout North Carolina. SAMS is capable of producing a reliable 70 cans per minute or up to 175 cases per hour with multiple can heights of 12 or 16 ounces and is fully scalable for future growth. AMB plans on releasing multiple beers in 22 ounce bottles late February and 12 ounce cans by mid July.

AMB is excited to officially announce the planned opening of its food service subsidiary which will offer a unique craft culinary experience. AMB expects to begin serving the High Country of North Carolina and AMB customers April 1, 2014. The Mobile Food Service will allow AMB to offer its wood-fired menu not only to AMB customers at the brewery but off-site catering and delivery service as well. AMB will not only be producing all of its own specialty doughs, but will infuse its award winning craft beers into wood-fired menu items which will make the food beyond exceptional. The Food Truck will employ solar panels, Bio-Diesel fuel, compostable utensils, and support the High Country’s farming community by purchasing locally. AMB’s continued focus on community building will be reflected thru our food service with the launching of its “Pies for Non-Profits” program. A portion of each sale will be donated to Non-Profits in and around the High Country further achieving our Philanthropic, Community, and Sustainability goals.

Additionally, AMB and Blood, Sweat and Gears, “BSG,” have announced an alliance whereby common philanthropic goals will be achieved. BSG Events is a 100% volunteer-based, fundraising non-profit organization featuring its 16^th annual cycling event where proceeds are donated to local charities in the High Country of North Carolina. The annual ride typically draws over 1,250 cyclists with more than 1,000 additional participants registered on a waiting list rating the event the “Top Century Ride in the South,” by Blue Ridge Outdoors magazine. Scott Nelson, Ride Director and President of BSG Events states, “The BSG/AMB alliance is one seldom found where we become more effective and efficient than we would as separate entities. Together, we can accomplish more as we rally support for our community giving back as much as possible, heading in the same direction and having the same philanthropic mindset but different tools. AMB’s tool is beer, ours is a bike ride,” states Nelson. “Both are squarely centered toward supporting local community non-profits and together are striving to reach new highs with a collaborative effort.” http://bloodsweatandgears.org/

AMB is continuing to explore its options for additional expansion in the Boone, NC area and hopes to secure an additional distribution center in 2014.

One of Appalachian Mountain Brewery’s shareholders, Mike Pruitt, CEO of Chanticleer Holdings, (Nasdaq:HOTR), has agreed to assist AMB with distribution of its beer into the restaurants it manages.   

About Appalachian Mountain Brewery, LLC

Appalachian Mountain Brewery, the Official Brewery of the Appalachian Mountains, not only makes seriously delicious craft beer, but focuses its business model on sustainability, community, and philanthropy. The company offers a unique experience through community stewardship and environmental sustainability as a core part of the business. The brewery’s modern equipment utilizes American Made JV Northwest Brewing Equipment, a 5kw array of solar panels to offset electricity along with a recapturing system to save water in the brew process.   In keeping with the brewery’s sustainable mission to reduce, reuse and recycle, AMB has a grain exchange program whereby all spent grain is donated to local farms. AMB also has a “Pints For Non-Profits Program,” whereby a portion of proceeds from each beer sold is donated to local non-profit organizations. AMB recently won two Gold Medals and won the overall categories in the 2013 United States Open Beer Championship for its Honey Badger Blonde Ale and California Common. AMB competed against the biggest and best breweries from around the world where over 2,500 beers competed in 68 categories for aroma, appearance, mouth feel, flavor and overall impression. Appalachian Mountain Brewery, located at 3,333 feet elevation atop the Appalachian Mountain Range in Boone, NC, is certified by the NC GreenTravel Initiative, a program that recognizes state travel-related businesses that employ healthy environmental practices. AMB is within minutes of world-class destinations such as Grandfather Mountain, Tweetsie Railroad, Beech Mountain, Sugar Mountain, Appalachian Ski Resorts and the three-time National Football Champions Appalachian State University.

For further information, please visit: www.appalachianmountainbrewery.com
Facebook: https://www.facebook.com/appalachianmountain.brewery
Awards: www.usopenbeer.com
Sustainability: http://portal.ncdenr.org/web/deao/ncgreentravel-attractionlist
Twitter: https://twitter.com/AMBrewery

About Chanticleer Holdings, Inc.

Chanticleer Holdings (Nasdaq:HOTR) is focused on expanding the Hooters® casual dining restaurant brand in international emerging markets and American Roadside Burgers Inc (“ARB”), a Charlotte, N.C. based chain. Chanticleer currently owns in whole or part of the exclusive franchise rights to develop and operate Hooters restaurants in South Africa, Hungary and parts of Brazil, and has joint ventured with the current Hooters franchisee in Australia, while evaluating several additional international opportunities. The Company currently owns and operates in whole or part of seven Hooters restaurants in its international franchise territories: Durban, Johannesburg, Cape Town and Emperor’s Palace in South Africa; Campbelltown in Australia; Budapest in Hungary; and Nottingham in the United Kingdom. ARB, purchased by Chanticleer Holdings on October 1, 2013, has a total of 5 casual restaurants — 1 location in Smithtown, N.Y., 2 locations in Charlotte, N.C., 1 location in Columbia, S.C., and the newest location is in Greenville, S.C. The Company also owns a majority interest in JF Restaurants, LLC and JF Franchising Systems, fresh food-focused casual dining established with 5 restaurant locations.

For further information, please visit www.chanticleerholdings.com
Facebook: www.Facebook.com/ChanticleerHOTR
Twitter: http://Twitter.com/ChanticleerHOTR

For further information on Hooters of America, visit www.Hooters.com
Facebook: www.Facebook.com/Hooters
Twitter: http://Twitter.com/Hooters

Safe Harbor

This press release contains forward-looking statements subject to the inherent uncertainties in predicting future results and conditions. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipate,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. Certain factors could cause actual results and conditions to differ materially from those projected in these forward-looking statements. We undertake no obligation to update such statements to reflect subsequent events.

CONTACT: Sean Spiegelman, CEO
         (828) 263-1111
         sean@appalachianmountainbrewery.com

(CYTR) Phase 2 Clinical Trial with Aldoxorubicin in AIDS-Related Kaposi’s Sarcoma

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi’s sarcoma (KS).

In this open-label Phase 2 clinical trial conducted at the Louisiana State University Health Sciences Center in New Orleans, up to 30 patients in three equal arms will be administered aldoxorubicin at 50, 100 or 150 mg/m2 by 30-minute intravenous infusion. Because the KS patients in the study have compromised immune systems, aldoxorubicin dosages administered to patients in the trial will be lower than those administered in CytRx’s clinical testing of aldoxorubicin in patients with soft tissue sarcomas. Patients will receive aldoxorubicin on day 1, then every 3 weeks until evidence of tumor progression, unacceptable toxicity or withdrawal of consent. The primary objective of preliminary efficacy will be determined through evaluation of the size, number and nodularity of skin lesions, and the Company will evaluate the level of aldoxorubicin uptake into lesions. Safety will be assessed through monitoring of adverse events and the ability to remain on assigned treatment.

“Aldoxorubicin has demonstrated effectiveness against a range of tumors in both human and animal studies, thus we are optimistic in regard to a potential treatment for Kaposi’s sarcoma. The current standard-of-care for severe dermatological and systemic KS is liposomal doxorubicin (Doxil®). However, many patients exhibit minimal to no clinical response to this agent, and that drug has significant toxicity and manufacturing issues,” said CytRx President and CEO Steven A. Kriegsman. “In addition to obtaining valuable information related to Kaposi’s sarcoma, this trial represents another opportunity to validate the value and viability of our linker technology platform.”

CytRx plans to discuss a pathway for the registration of aldoxorubicin for KS with the FDA if the data are positive. The Company expects to announce data from this Phase 2 clinical trial in the second quarter of 2015.

Kaposi’s sarcoma is an orphan indication. In the United States, under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease that affects fewer than 200,000 individuals in the country. The designation grants U.S. market exclusivity to a drug for a particular indication for a seven-year period if the sponsor complies with certain FDA requirements. Additional incentives for the sponsor include tax credits related to clinical trial expenses and a possible exemption from the FDA-user fee.

About Kaposi’s Sarcoma

Kaposi sarcoma is a cancer that causes lesions (abnormal tissue) to grow in the skin; the mucous membranes lining the mouth, nose, and throat; lymph nodes; or other organs. The lesions are usually purple and are made of cancer cells, new blood vessels, red blood cells, and white blood cells. Kaposi sarcoma is different from other cancers in that lesions may begin in more than one place in the body at the same time. KS remains the most common HIV-associated tumor worldwide.

About Aldoxorubicin

The widely used chemotherapeutic agent doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 450 mg/m². Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to circulating albumin, the most plentiful protein in the bloodstream. Protein-hungry tumors concentrate albumin, thus increasing the delivery of the linker molecule with the attached doxorubicin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released. This allows for greater doses (3 ½ to 4 times) of doxorubicin to be administered while reducing its toxic side effects. In studies thus far there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of drug well in excess of 2 g/m².

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for soft tissue sarcomas, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx plans to initiate under a special protocol assessment a pivotal Phase 3 global trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy, and recently announced that it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in that clinical trial. CytRx has initiated a Phase 2 clinical trial with aldoxorubicin in patients with late-stage glioblastoma (brain cancer), and a Phase 2 clinical trial in HIV-related Kaposi’s sarcoma. CytRx plans to expand its pipeline of oncology candidates based on a linker platform technology that can be utilized with multiple chemotherapeutic agents and may allow for greater concentration of drug at tumor sites. CytRx also has rights to two additional drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib. For more information about CytRx Corporation, visit www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks relating to the outcome, timing and results of CytRx’s clinical trials, the risk that any future human testing of aldoxorubicin, including the Phase 2 study of aldoxorubicin for the treatment of HIV-infected patients with Kaposi’s sarcoma, might not produce results similar to those seen in past human or animal testing, risks related to CytRx’s ability to manufacture its drug candidates in a timely fashion, cost-effectively or in commercial quantities in compliance with stringent regulatory requirements, risks related to CytRx’s need for additional capital or strategic partnerships to fund its ongoing working capital needs and development efforts, including the Phase 3 clinical development of aldoxorubicin, and the risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(EVOK) Positive Study Results For Metoclopramide Nasal Spray

SAN DIEGO, Jan. 22, 2014  — Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide.

The Phase 2b study, which was published online ahead-of-print for an upcoming issue of Neurogastroenterology & Motility, enrolled 89 patients from six study sites throughout the United States. The multicenter, randomized, open-label, parallel design study was the first to compare the efficacy and safety of metoclopramide nasal spray to oral tablets in diabetic patients with symptoms of gastroparesis when dosed four times a day for 6 weeks.

Marilyn Carlson, D.M.D., M.D., RAC, Chief Medical Officer of Evoke, said, “It is intuitive that a nasal spray will have more reliable absorption than a tablet in patients with delayed gastric emptying. These data from symptomatic diabetic gastroparesis patients confirm that metoclopramide nasal spray is well-tolerated and can offer better symptom relief than a tablet in this population.”

“We believe the results from our Phase 2b clinical trial validate our novel intranasal delivery system of metoclopramide (EVK-001) which will be evaluated soon in our upcoming Phase 3 clinical trial,” said Dave Gonyer, R.Ph., President and Chief Executive Officer of Evoke. “There haven’t been any new drugs for the management of symptoms associated with gastroparesis approved by the FDA since 1980, and there are very few drugs in clinical development for this debilitating diabetic complication.”

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.

Safe Harbor Statement

Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: the ability of a nasal spray to offer better symptom relief than a tablet in diabetic patients with symptoms of gastroparesis; the upcoming Phase 3 clinical trial; and the market opportunity for EVK-001. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risk and uncertainties inherent in Evoke’s business, including, without limitation: the inherent risks of clinical development of EVK-001, including potential delays in enrollment and completion of clinical trials, including the planned Phase 3 trial; Evoke will require substantial additional funding, including potentially to complete the planned Phase 3 clinical trial of EVK-001 as well as to finance additional development requirements, and may be unable to raise capital when needed; the results observed in the Phase 2b study may not be predictive of the safety and efficacy results in the planned Phase 3 clinical trial or any other future trial; the potential for adverse safety findings relating to EVK-001 to delay or prevent regulatory approval or commercialization; Evoke’s reliance on outsourcing arrangements for many of its activities, including clinical development and supply of EVK-001; competition from other pharmaceutical or biotechnology companies; and other risks detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

CONTACT: Investor Contact:
         The Ruth Group
         David Burke/Stephanie Carrington
         Tel: 646-536-7009/7017
         dburke@theruthgroup.com
         scarrington@theruthgroup.com

         Media Contact:
         The Ruth Group
         Aaron Estrada
         Tel: 646-536-7028
         aaestrada@theruthgroup.com

(VISN) Announces Exclusive Strategic Cooperation with Baidu Games

BEIJING, Jan. 22, 2014  — VisionChina Media Inc. (“VisionChina Media” or the “Company”) (Nasdaq: VISN), one of China’s largest out-of-home digital television advertising networks on mass transportation systems, today announced that it has entered into an exclusive strategic cooperation agreement (“Agreement”) with Baidu Games, the online game platform of Baidu, Inc. (NASDAQ:BIDU), to promote the Baidu Games brand and Baidu’s gaming products across VisionChina Media’s digital television advertising networks nationwide.

Under the terms of the Agreement, VisionChina Media will act as the exclusive digital mobile television advertising partner of Baidu Games and provide brand promotion and advertising placement solutions for Baidu Games throughout VisionChina Media’s national media networks on buses and subways in 2014.

“We are proud to announce this exclusive strategic cooperation with Baidu Games,” said Mr. Limin Li, VisionChina Media’s chairman and chief executive officer. “This deal is representative of our advertising service capabilities and the success we’ve had in working with China’s gaming industry. With our ability to reach, through both exclusive and non-exclusive partnerships, China’s above-ground bus networks in 88 cities and underground subway networks in 14 cities, covering nearly 600 million person-time on daily basis, we are an ideal fit for helping Baidu Games raise its brand profile and improve its penetration and conversion rates in turning offline audiences into new online players. Furthermore, our cooperation with Baidu Games will further solidify our leading position with respect to gaming advertising and promotion in China’s out-of-home media sector.”

About VisionChina Media Inc.

VisionChina Media Inc. (Nasdaq: VISN) operates an out-of-home advertising network on mass transportation systems, including buses and subways. As of September 30, 2013, VisionChina Media’s advertising network included 110,383 digital television displays on mass transportation systems in 19 of China’s economically prosperous cities, including Beijing, Guangzhou and Shenzhen, as secured by exclusive agency agreements or joint venture contract. VisionChina Media has the ability to deliver real-time, location-specific broadcasting, including news, stock quotes, weather and traffic reports, and other entertainment programming.For more information, please visit http://www.visionchina.cn.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates” and similar statements. Among other things, the quotations from management in this press release contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its registration statement on Form F-1 and its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For investor and media inquiries, please contact:

In China:

Ms. Shuning Yi
Investor Relations Department
VisionChina Media Inc.
Tel: +86-134-2090-9426
E-mail: shuning.yi@visionchina.cn

Mr. Colin Wang
Investor Relations Director
VisionChina Media Inc.
Tel: +86 135-1001-0107
Email: colin.wang@visionchina.cn

In the United States:

Mr. Justin Knapp
Ogilvy Financial, U.S.
Tel: +1-616-551-9714
E-mail: visn@ogilvy.com

(SMCI) Supermicro® Shipping Complete Line of A+ G34 Server Solutions

Single, Dual and Quad Socket Solutions Deliver up to 27% Better Performance per Watt per Dollar with Latest AMD 12 and 16-Core “Warsaw” CPUs

SAN JOSE, Calif., Jan. 22, 2014  — Super Micro Computer, Inc. (NASDAQ: SMCI), a global leader in high-performance, high-efficiency server, storage technology and green computing announces it is shipping new single, dual and quad socket G34 motherboards and server solutions with the latest AMD Opteron™ 6300 series processors built on 32nm “Piledriver” microarchitecture. Supermicro A+ motherboards, server and SuperBlade® solutions maximize energy efficiency with airflow optimized designs for best thermal operation and high efficiency power supplies. Combined with new low power (99W TDP) Opteron™ 6338P (12-Core) and 6370P (16-Core) processors, Supermicro’s A+ G34 platforms deliver up to 27%* better performance per watt, per dollar when compared with higher end 6300 series solutions. These new server solutions complement existing high-performance Opteron-based product lines with a new cost-effective, energy efficient range of G34 server platforms. Highlights of the new G34 server solutions include 1U single processor servers for the SMB and Enterprise (AS-1012G-MTF), 1U/2U/Twin architecture, dual processor servers (AS-1122G-URF4+, AS-2022G-URF4+, 2U Twin² Series AS-2022TG/2122TG) for high-density, scalable data center, cloud and virtualization applications and quad processor 1U/2U/4U/Tower/Blade systems (AS-1042G-TF, AS-2042G-TRF/-72RF4, AS-4042G-72RF4, SBA-7222G-T2) for high performance computing (HPC) clusters.

“Supermicro is unrivaled in the industry, offering the strongest line of Data Center, Cloud and HPC optimized single, dual and quad socket motherboard, server and blade configurations supporting AMD’s new lower power Opteron 6338P/6370P processors,” said Don Clegg, Vice President of Marketing and Business Development at Supermicro. “With an amazing 27% boost in performance per watt, per dollar, our extensive selection of Warsaw-based server building block solutions provides customers with a new range of energy efficient server options to lower their overall TCO.”

“Our new AMD Opteron 6338P and 6370P processors were designed to deliver optimized performance per watt per dollar, and to address the complex data center and cloud computing challenges customers face today,” said Suresh Gopalakrishnan, corporate vice president and general manager, Server Business Unit at AMD. “With Supermicro’s strong suite of server solutions shipping with our new AMD Opteron 6300 processors, customers can immediately deploy cost-optimized solutions tailored for their specific applications and take complete advantage of low power and high density without a compromise in performance.”

(Info: http://photos.prnewswire.com/prnh/20140122/AQ50508-INFO)

A+ AMD Opteron™ 6000 (G34) Series Servers, Motherboards and Blades
New Generation Opteron™ 6000/4000/3000 family based platforms, download the latest A+ Server Brochure
Visit www.supermicro.com for the widest selection of end-to-end server, storage, networking and data center management solutions.

* 27% higher performance per watt, per dollar determined by SPECfp®

Follow Supermicro on Facebook and Twitter to receive their latest news and announcements.

About Super Micro Computer, Inc.
Supermicro® (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/Big Data, HPC and Embedded Systems worldwide. Supermicro is committed to protecting the environment through its “We Keep IT Green®” initiative and provides customers with the most energy-efficient, environmentally-friendly solutions available on the market.

Supermicro, SuperServer, SuperBlade, Building Block Solutions and We Keep IT Green are trademarks and/or registered trademarks of Super Micro Computer, Inc.

All other brands, names and trademarks are the property of their respective owners.

SMCI-F

(LUNA) Announces Sale of Shape-Sensing Technology for Medical Applications

Luna Innovations Incorporated (NASDAQ:LUNA), which develops and manufactures new-generation products for the telecommunications, aerospace, automotive, energy and defense markets, today announced the sale of its shape-sensing technology for medical applications to Intuitive Surgical, Inc. (NASDAQ:ISRG).

The terms of the deal include Luna receiving $12 million upfront in two tranches and up to an additional $18 million upon certain technical milestones and commercial measures. Intuitive will acquire Luna’s fiber optic shape-sensing and localization technology, including related patents, and hire a number of engineering employees formerly utilized in Luna’s medical shape-sensing business.

The sale will enable Luna to focus on the growth potential of its fiber-optic sensing business while significantly strengthening the company’s balance sheet. The sale contains provisions that maintain Luna’s ability to service its existing agreements and for the continued use and exploration of opportunities outside the medical industry.

“Luna develops technological solutions to problems that others cannot solve, and this is yet another successful example of how our technology ultimately reaches the market, in this case with a long-time development partner,” said Luna President and CEO My Chung. “This sale is the culmination of the shape-sensing development we’ve done over the past several years for potentially integrating into Intuitive’s future products. One of the many benefits of this agreement is the ability to monetize much of the value of our innovations immediately – rather than waiting for longer-term revenues from development and potential supply agreements – while enabling us to streamline our focus on the growth opportunities that we believe exist for our strain/temperature sensing business, especially within the automotive and aerospace markets.”

“We look forward to working with Luna on a smooth transition,” said David Larkin, Intuitive’s Vice President of Engineering. “We are excited about the team joining Intuitive and the possibilities around this technology.”

With the sale, Luna will focus on growing its fiber optic sensing technology, which improves manufacturing and testing of composite and non-composite materials, structures and systems. “With strain and temperature sensing now as our key focus, we’re prepared to develop technological solutions for this growing market with our proven technology,” Chung said. ”We also will continue to sell our test and measurement products to the telecommunications industry and develop a pipeline of technologies through contract research.”

Mr. Chung and Dale Messick, Luna’s Chief Financial Officer will host a conference call with investors on Thursday, January 23, 2014 at 9:00 a.m. (EST) to discuss the transaction. The conference call will be available via live webcast on the Luna website at www.lunainc.com under the tab “Investor Relations”. To participate by telephone, the domestic dial-in number is 800.706.7745 and the international dial-in number is 617.614.3472. The participant access code is 14875088. Investors are advised to dial in at least five minutes prior to the call to register. The webcast will be archived on the company’s website under “Webcasts and Presentations” for 30 days following the conference call.

About Luna

Luna Innovations Incorporated (www.lunainc.com) is a public company composed of scientists, engineers, and business professionals developing and manufacturing a new generation of technologies and products. It has been successful in taking innovative technologies from applied research to product development and ultimately to the commercial market, driving breakthroughs in fields such as aerospace, automotive, telecommunications, healthcare, energy, and defense.

About Intuitive

Intuitive Surgical, Inc. (NASDAQ:ISRG) is the global technology leader in robotic-assisted minimally invasive surgery (MIS). The Company’s da Vinci® Surgical System offers surgeons superior visualization, enhanced dexterity, greater precision and ergonomic comfort for the optimal performance of MIS. The da Vinci System enables surgeons to perform even complex procedures such as open-heart surgery through 1-2 cm incisions.

Forward Looking Statements

This release includes information that constitutes “forward-looking statements” made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements regarding, but not limited to: Luna’s potential future receipt of deferred and contingent payments, including royalties, in connection with the transaction; Luna’s focus on markets outside of the medical industry; the uniqueness of Luna’s technology and intellectual property; potential for future commercialization of its technologies; the competitive advantage afforded by Luna’s technology; the potential efficacy of Luna’s technology; growth potential of certain markets and potential benefits of the incorporation of Luna’s shape-sensing technology in robotic and non-robotic surgery and Intuitive’s ability to improve the delivery of healthcare by virtue of the transaction. Statements that describe the company’s business strategy, goals, prospects, opportunities, outlook, plans or intentions are also forward-looking statements. Actual results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including the ability of the technology transferred to Intuitive to achieve certain technical specifications that are required for triggering future payment under the asset purchase agreement, Intuitive’s successful development of surgical systems incorporating the Luna technology; approval of such systems for marketing by the United States Food and Drug Administration and similar foreign regulatory bodies; market adoption of Intuitive surgical systems incorporating Luna technology; uncertainties regarding the growth of the markets for the company’s temperature and strain sensing technology outside of the medical industry; technical and scientific difficulties; issues that might arise in any particular business relationship; and risks and uncertainties set forth in the company’s periodic reports and other filings with the Securities and Exchange Commission. Such filings are available at the SEC’s website at http://www.sec.gov, and at the company’s website at http://www.lunainc.com. The statements made in this release are based on information available to the company as of the date of this release and Luna undertakes no obligation to update any of the forward-looking statements after the date of this release.

(VNRX) Commences First Large Clinical Trial in Collaboration With Hvidovre Hospital, Denmark

(DMRC) and Intellectual Ventures Settle Disputes, Strengthen Business Relationship

(AMZG) to Host The Oil & Services Conference 12, February 18-19, in San Fran

DENVER, Jan. 21, 2014  — EnerCom, Inc. will host The Oil & Services Conference™ 12 (TOSC 12) from February 18-19, 2014, at the Omni San Francisco Hotel.  Institutional investors, energy research analysts, and oil and gas investors can register to attend, and find the work-in-progress presenter schedule at The Oil & Services Conference™ website.

EnerCom’s The Oil & Services Conference™ 12 is a well-attended major investment forum featuring presentations from E&P and OilService companies, energy research analysts, and industry thought-leaders. Founded in 2003 by EnerCom, The Oil & Services Conference™ annually brings together executives and investment professionals focused on the global oil and gas industry. Global conference sponsors of TOSC 12 are Credit Agricole Corporate and Investment Bank, Netherland, Sewell & Associates, Preng & Associates, Hein & Associates, and Wunderlich Securities.

EnerCom’s TOSC 12 Investment Conference Forum:

• Each presenter will deliver a 25-minute presentation to a live and global investment audience.
• Breakout sessions for Q&A will immediately follow each presentation.
• Institutional investors and research analysts can schedule one-on-one meetings with presenting companies by contacting EnerCom prior to TOSC 12.
• EnerCom will report company highlights and new developments in real-time using the Twitter hash-tag #TOSC12.

Presenting Company Performance

Investors attending TOSC have benefited from their participation.  Since the Conference’s founding in 2003, the collected group of presenting companies have generated a return of more than 290%, which compares favorably to the OSX Index and associated commodity prices.  It’s the people that are drilling and producing the oil and gas assets from which investors benefit. A TOSC Index performance chart can be found here.

Discussion Themes for TOSC 12

Industry analysts believe 2014 capital spending budgets will hit new record levels as exploration and production companies pour billions of drilling and completion dollars into oil and natural gas regions such as the Marcellus, Utica, Eagle Ford, Bakken/Three Forks, Permian, Niobrara, and Gulf of Mexico. Consequently, more spending will place even greater pressure on Washington to revisit our nation’s export guidelines as crude and natural gas stockpiles continue to grow at a rapid pace.

About EnerCom, Inc.

Founded in 1994, EnerCom, Inc. is a nationally recognized investor communications consultancy firm advising and serving energy-centric clients on corporate strategy, investor relations, media and corporate communications, and visual communications design.  The Company’s professionals have more than 150 years of industry and business experience and a proven track record of success. Headquartered in Denver, EnerCom uses the team approach for delivering its wide range of services to public and private companies large and small, operating in the global exploration and production, drilling, OilService, and associated advanced-technology industries. The Company annually hosts three oil and gas investment conferences:

• The Oil & Services Conference™ 12 – San Francisco, California – February 18-19, 2014
• EnerCom’s London Oil & Gas Conference™ 6 – London, England – June 2014
• The Oil & Gas Conference® 19 – Denver, Colorado – August 17-21, 2014

For more information about EnerCom, its services, Conferences and Oil & Gas 360® please call +303-296-8834.

About Credit Agricole Corporate and Investment Bank

Credit Agricole Corporate and Investment Bank, the corporate and investment banking arm of the Credit Agricole Group, has more than 13,000 professionals operating in more than 50 countries.  It provides its clients with a complete range of products and services in the areas of structured finance and commercial banking, capital markets, brokerage, and investment banking.

With headquarters in New York City, and U.S. offices in Houston, and Chicago, Credit Agricole CIB Americas offers its corporate and institutional clients financial products and services and made-to-order structuring, origination and distribution, through both its banking unit Credit Agricole CIB, and the full service broker-dealer Credit Agricole Securities (USA) Inc., which is a member of both the NYSE and FINRA.  Credit Agricole CIB is also present in Montreal, Canada, and in Latin America with offices in Argentina, Brazil, and Mexico.

The Energy Industry represents the single largest concentration of industry exposure at Credit Agricole Corporate and Investment Bank, whose specialty focus dates back over 100 years.  Our Energy practice for North America, located in Houston, focuses on all segments of the business and covers it on a truly global basis.

About Netherland, Sewell & Associates, Inc.

Netherland, Sewell & Associates, Inc. (NSAI) was founded in 1961 to provide the highest quality engineering and geological consulting to the petroleum industry.  Today they are recognized as the worldwide leader of petroleum property analysis to industry and financial organizations and government agencies.  With offices in Dallas and Houston, NSAI provides a complete range of geological, geophysical, petrophysical, and engineering services and has the technical experience and ability to perform these services in any of the onshore and offshore oil and gas producing areas of the world. They provide reserves reports and audits, acquisition and divestiture evaluations, simulation studies, exploration resources assessments, equity determinations, and management and advisory services.  For a complete list of services or to learn more about Netherland, Sewell & Associates, Inc. please visit www.netherlandsewell.com.

For more information about NSAI, call C.H. (Scott) Rees, Chief Executive Officer, at 214-969-5401 or send an email to info@nsai-petro.com.

About Preng & Associates

Preng & Associates, founded in 1980, is the only retainer-based, international executive search firm specializing solely in the energy industry.  Its number one priority is to assist clients with their executive selection, organization development, and human resource needs by providing the highest quality service. Preng’s record of accomplishment is directly attributable to their experienced staff, worldwide network of industry contacts, proven search methodology, and high standards of professionalism.  Preng has conducted over 3000 searches for board, executive, management, and professional positions in its 31-year history and has the highest success and repeat client track record.

Preng’s practice is based on the premise that the search process is most effective when conducted by professionals with significant search industry experience.  The company has earned a reputation for combining professional search disciplines with an in-depth industry and market understanding and has succeeded in some of the industry’s most challenging and high-profile searches.  Preng’s international reach allows it to effectively conduct global engagements; and as a member of the Association of Executive Search Consultants, Preng practices and promotes its high standards of conduct and professionalism.

For more information about Preng & Associates, contact Charles Carpenter, Partner at 713-243-2610 or ccarpenter@preng.com. 

About Hein & Associates

For more than 30 years, Hein & Associates has been recognized as a leading accounting and advisory firm where its people and clients share knowledge, thrive in a culture of teamwork, and build long-term relationships deeply rooted in integrity.  With offices in Denver, Dallas, Houston and Irvine, Hein serves public and private companies in a variety of industries across the country.  Hein also serves clients globally through its alliance with associations of independent accounting firms around the world. Hein is ranked as one of the “Top 100” accounting and advisory firms in the country by Accounting Today, and consistently recognized by Inside Public Accounting as a “Best of the Best” firm, an honor bestowed on only 25 firms each year, based exclusively on management performance.

For more information, please contact Brian Mandell-Rice, Managing Partner, at bmandell-rice@heincpa.com, 303.298.9600 or visit www.heincpa.com.

About Wunderlich Securities

Established in 1996 in Memphis, TN, Wunderlich Securities, a full-service brokerage firm, is committed to providing a comprehensive range of professional products and services to meet the needs of individual investors as well as corporations and institutions. The Firm offers financial advisory, brokerage, equity research and investment banking services. Fixed Income broker services are provided through Wunderlich Securities Fixed Income Capital Markets and WunTrade divisions of Wunderlich Securities. The firm operates in 26 offices across 15 states and has more than 450 associated professionals.

For more information, please contact R. Kevin Andrews, Managing Director, Investment Banking, at (713) 403-3979 or visit www.wunderlichsecurities.com.